MGTA News and Press, Magenta Therapeutics Inc. From 02/27/21

For patients with certain blood cancers, a stem cell transplant can often be a curative treatment. However, it is also a complex process riddled with severe toxicities and high rates of relapse or failure. These issues are at least part of the reason why only about 60% of cancer patients, a...

Gain Therapeutics has filed to raise $40 million in a U.S. IPO. The firm is a preclinical biopharma developing treatments for lysosomal storage disorders. GANX has a number of research collaborations, but is still at a very early stage of development, so maybe more relevant for in...

– Magenta will present a total of five abstracts, including four oral presentations, highlighting clinical and preclinical data across its portfolio – Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to ...

The following slide deck was published by Magenta Therapeutics, Inc. in conjunction with this event. For further details see: Magenta Therapeutics (MGTA) Presents At 39th Annual J.P. Morgan Healthcare Conference - Slideshow

Magenta Therapeutics (MGTA) has announced four pipeline-expanding partnerships, presented clinical and pre-clinical data across our pipeline and secured the capital that we expect can fund our operations into 2023.MGTA-145: Three phase 2 clinical trials ongoing or planned. Initial data from t...

-- MGTA-145: Three Phase 2 clinical trials ongoing or planned to evaluate MGTA-145, a biologic used in combination with plerixafor to mobilize stem cells; the first clinical trial in patients with multiple myeloma (initial data expected in mid-2021); the first clinical trial with matc...

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company is scheduled to present at the 39 th Annual J.P. Morgan Healthcare Conference...

– Enrollment commenced in the MGTA-145 Phase 2 clinical trial of autologous transplant of multiple myeloma patients at Stanford University – – Oral presentation of Phase 1 clinical data presented at the 62 nd American Society of Hematology (ASH) Annual...

Magenta Therapeutics (MGTA) and bluebird bio (BLUE) have entered into clinical trial collaboration to evaluate MGTA-145, a CXCR2 agonist, in combination with plerixafor, a CXCR4 antagonist, for mobilization and collection of stem cells in patients with sickle cell disease.Under...

Magenta Therapeutics (NASDAQ: MGTA) and bluebird bio, Inc. (NASDAQ: BLUE) today announced an exclusive clinical trial collaboration to evaluate the utility of MGTA-145, in combination with plerixafor, for mobilization and collection of stem cells in adults and adolescents with sickl...